期刊
VACCINES
卷 11, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/vaccines11091440
关键词
immunogenic cell death; nanotechnology; tumor vaccines; cancer immunotherapy
This review summarizes the latest studies on nanotechnology-mediated immunogenic cell death for effective cancer immunotherapy and highlights the challenges.
Tumor vaccines have been used to treat cancer. How to efficiently induce tumor-associated antigens (TAAs) secretion with host immune system activation is a key issue in achieving high antitumor immunity. Immunogenic cell death (ICD) is a process in which tumor cells upon an external stimulus change from non-immunogenic to immunogenic, leading to enhanced antitumor immune responses. The immune properties of ICD are damage-associated molecular patterns and TAA secretion, which can further promote dendritic cell maturation and antigen presentation to T cells for adaptive immune response provocation. In this review, we mainly summarize the latest studies focusing on nanotechnology-mediated ICD for effective cancer immunotherapy as well as point out the challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据